EU Lead Factory (ELF) and CELLIPSE announced today completion of the 1st phase of their collaboration program to identify hits against an undisclosed innovative therapeutic target that is involved in cytoskeleton regulation.
The qualified hit list delivered to CELLIPSE was obtained from a screening program on ELF’s Joint European Compound Library that included more than 400,000 (now 450,000) compounds. The screening effort was led by Pivot Park Screening Centre, with support from the University of Oxford, University of Dundee, Newhouse and CELLIPSE.
During the 57th American Society of Hematology Congress held in Orlando, the teams from U. of Indiana Wells Center led by Pr Kapur and Institut Albert Bonniot led by Dr Lafanechère presented the results of their work in the session dedicated to Oncogene and Tumor Suppressors in Myeloïd malignancies. This new data reinforces the rationale for looking into LIM Kinase inhibition to stop downstream oncogene signaling of specific mutations of Tyrosine Kinase Receptors.
COinside, le projet porté par SynapCell, Cellipse et Grenoble Institut des Neurosciences (équipes d’Annie Andrieux et Alain Buisson), a été retenu à l’issue du Concours du Fonds Unique Interministériel 19 et sera financé par les industriels avec le soutien de la Métropole Grenobloise, la région Rhône-Alpes et l’Etat.
CELLIPSE was awarded an exclusive High Thoughput Screening research to screen the EU Lead Factory joint compound library on an undisclosed innovative target, by the Screening Selection Committees of EU Lead Factory (ELF) on January 19 2015.
As of January 2014, CELLIPSE is moving into its new 100 sq. meter state-of-the-art facilities in the Minatec building on the CEA Grenoble Campus.
The CELLIPSE LIMINIB project presented by its CEO Fabrice Paublant was selected as National Laureate in the category Healthcare / Biotech by the Jury of the Ministry of Research and Education (Laureate CNACETI Créa/Dev. 2013).
LIMLEAD is an applied research collaboration project between Institut Albert Bonniot, Grenoble and CELLIPSE.